Swipe tables sideways to see all columns.
Research findings
Comparative structure study
The largest recorded reporting jurisdiction, Jiangsu, contains 9 records (30.0% of this 30-record cohort). The remaining cohort contains 21 records. The comparison concerns archive composition.
The recorded chain role label Biomedicine and medical devices / Complete systems and use-case applications accounts for 86.7% here (26/30), compared with 7.1% in the parent set (1,373/19,297), an absolute gap of 79.6 percentage points.
13/30 companies link to pages with existing source-supported excerpts (43.3% of the cohort). The other 17 records remain usable for archive composition, but do not support new operating case studies.
6 keyword candidates match only a company name, with no matching term in recorded products or sub-industry fields. Product evidence is needed before treating these as operating businesses in this segment.
| Company cohort | Directly linked pages | Share of public archive | Archive date |
|---|---|---|---|
| 30 | 30 | 0.2% | 2026-10-16 |
An ID-deduplicated archive snapshot, not the whole market, current recognition or operating results.
Comparable sets and compositional differences
The parent set, All public archive records, contains 19,297 records. This cohort contributes 30 (0.2%); 19,267 records remain after excluding it.
| Category | Cohort count/base | Reference: All public archive records | Gap (pp) | Representation ratio | Rest count/base |
|---|---|---|---|---|---|
| chain role · Biomedicine and medical devices / Complete systems and use-case applications | 26/30 · 86.7% | 1,373/19,297 · 7.1% | +79.6 | 12.18 | 1,347/19,267 |
| industry · Biomedicine | 25/30 · 83.3% | 1,721/19,297 · 8.9% | +74.4 | 9.34 | 1,696/19,267 |
| sub-industry · Biomedicine | 9/30 · 30.0% | 699/19,297 · 3.6% | +26.4 | 8.28 | 690/19,267 |
| sub-industry · In vitro diagnostics | 5/30 · 16.7% | 32/19,297 · 0.2% | +16.5 | 100.51 | 27/19,267 |
| reporting jurisdiction · Jiangsu | 9/30 · 30.0% | 3,025/19,297 · 15.7% | +14.3 | 1.91 | 3,016/19,267 |
| reporting jurisdiction · Shenzhen | 5/30 · 16.7% | 1,398/19,297 · 7.2% | +9.4 | 2.30 | 1,393/19,267 |
Ratio of label participation, not market share; multi-label counts overlap.
Excluding this cohort, the recorded chain role label Biomedicine and medical devices / Complete systems and use-case applications covers 1,347/19,267 remaining records (7.0%), an absolute gap of 79.7 percentage points from this cohort.
Concentration and cross-sectional structure
The full reporting jurisdiction distribution has 14 labels; the top 3 contain 17/30 records (56.7%).Other known labels contain 13 records.
For 30 records with known labels, the effective category count is 6.8, versus 14 actual labels. Definitions and scope are in the methodology.
The table shows ten labels; 4 others are included in the calculations above.
| Recorded label | Records | Share of cohort |
|---|---|---|
| Jiangsu | 9 | 30.0% |
| Shenzhen | 5 | 16.7% |
| Hunan | 3 | 10.0% |
| Beijing | 2 | 6.7% |
| Shandong | 2 | 6.7% |
| Shanghai | 1 | 3.3% |
| Sichuan | 1 | 3.3% |
| Tianjin | 1 | 3.3% |
| Guangdong | 1 | 3.3% |
| Xinjiang Production and Construction Corps | 1 | 3.3% |
Record counts do not rank supply capability or economic size.
The largest intersection, Jiangsu × Biomedicine, contains 6 records, or 66.7% of the 9 records carrying the Jiangsu label.
| reporting jurisdiction | industry | Intersection records | Cohort share |
|---|---|---|---|
| Jiangsu | Biomedicine | 6 | 20.0% |
| Shenzhen | Biomedicine | 4 | 13.3% |
| Hunan | Biomedicine | 3 | 10.0% |
| Beijing | Biomedicine | 2 | 6.7% |
| Shandong | Biomedicine | 2 | 6.7% |
| Shanghai | Biomedicine | 1 | 3.3% |
| Sichuan | Biomedicine | 1 | 3.3% |
| Tianjin | Biomedicine | 1 | 3.3% |
A cell contains company IDs carrying both labels. It does not establish procurement, supply or investment relationships between firms. Multi-label cells may overlap.
This page displays 8 of the full cross-tab’s 18 non-empty cells; the other 10 remain in the analysis.
Evidence coverage and strength of conclusions
| Record field | Non-empty/cohort | Completion |
|---|---|---|
| Company name | 30/30 | 100.0% |
| reporting jurisdiction | 30/30 | 100.0% |
| industry | 30/30 | 100.0% |
| Recorded products | 30/30 | 100.0% |
| sub-industry | 30/30 | 100.0% |
| Chain labels | 30/30 | 100.0% |
Non-empty fields are not necessarily accurate or supported by originals.
| Scope of source support | Count |
|---|---|
| Profiles with source-supported excerpts | 13 |
| Distinct corresponding companies | 13 |
| Reviewed Chinese/English paragraph pairs | 13 |
Counts concern existing reviewed bilingual excerpts, not re-certification of originals or entire reports.
| Transparent rule reminder | Records | Cohort share |
|---|---|---|
| Contains registration-narrative wording | 1 | 3.3% |
A rule hit prioritises review; it does not establish that the entire field is wrong. One record can trigger several rules.
| Matched field | Candidates | Cohort share |
|---|---|---|
| Company name | 6 | 20.0% |
| Recorded products | 20 | 66.7% |
| Sub-industry | 7 | 23.3% |
An ID may match several fields, so counts may exceed the cohort total. Matches establish search relevance only.
Among the translated non-broad query terms, “biological products” has the most matches: 14/30. Name, product and sub-industry fields match 6, 4 and 5 records respectively; the largest field is name. Fields can overlap, and a term remains a search link rather than verified business activity.
| Selected query term | Candidates/share | Name matches | Product field | Sub-industry |
|---|---|---|---|---|
| biological products | 14 · 46.7% | 6 | 4 | 5 |
Selected broad terms and specific segment terms, not the full query. Terms and fields can overlap and must not be summed. Counts show lexical sensitivity; no records are removed without primary evidence.
6 candidates match only a name, or lose all product-field matches after the full company name is removed while sub-industry also has no hit. This transparent string test locates copied company descriptions; it does not establish that a company does not operate the business.
Intersection with 2026 local lists
10 of this cohort’s 30 records link through existing company-ID mappings to 2026 lists from all jurisdictions (33.3%). This intersection measures list linkage, not successful recognition or company growth.
| Observation set | List records | New-applicant records | Review records | Mapped company IDs |
|---|---|---|---|---|
| National list records linked to this cohort’s IDs | 10 | 0 | 10 | 10 |
List rows and company IDs are separate counts, not new firms or final recognition.
Stored 2026 local-recommendation records, sources and stage definitionsRecorded roles and delivery checks
Related studies and shared records
Shared records with Poct Biosensor Diagnostics Keyword Candidate Study: 11; records in this cohort but outside that set: 19. The intersection/union ratio is 34.4%, a measure of label overlap rather than business collaboration. Read comparison
Shared records with Industrial Solvents Reagents High Purity Chemicals Keyword Candidate Study: 12; records in this cohort but outside that set: 18. The intersection/union ratio is 18.8%, a measure of label overlap rather than business collaboration. Read comparison
Company samples and record links
| Company | Jurisdiction | Recorded industry |
|---|---|---|
| Xinghua GL Stevia Co., Ltd. | Jiangsu | Biomedicine |
| Hunan Runkun Pharmaceutical Co., Ltd. | Hunan | Biomedicine |
| Xinjiang Chen Guang Biotech Co., Ltd. | Xinjiang Production and Construction Corps | Biomedicine |
| Jiangsu Xinruibei Biotechnology Co., Ltd. | Jiangsu | Advanced chemicals |
| Guangzhou LBP Medicine Science & Technology Co., Ltd. | Guangdong | Biomedicine |
| Shenzhen Bioeasy Biotechnology Co., Ltd. | Shenzhen | Biomedicine |
| Lisure Science(Suzhou) Co., Ltd. | Jiangsu | Biomedicine |
| Rayto Life and Analytical Sciences Co., Ltd. | Shenzhen | Biomedicine |
Stable-ID samples, not rankings; metrics use the full cohort.
Directly related profiles and reports
| Page | Presentation |
|---|---|
| Xinghua GL Stevia Co., Ltd. | Company data profile |
| Hunan Runkun Pharmaceutical Co., Ltd. | Company data profile |
| Xinjiang Chen Guang Biotech Co., Ltd. | Company report page |
| Jiangsu Xinruibei Biotechnology Co., Ltd. | Company data profile |
| Guangzhou LBP Medicine Science & Technology Co., Ltd. | Company data profile |
| Shenzhen Bioeasy Biotechnology Co., Ltd. | Company data profile |